Screener
iRadimed IRMD Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by iRadimed in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: iRadimed’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029325
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Deferred revenue, non-current | 3,757 | 3,978 |
| Total liabilities | $15,875 | 14,158 |
| Stockholders’ equity: | ||
| Common stock; $0.0001 par value per share; 31,500,000 shares authorized; 12,782,837 shares issued and outstanding as of March 31, 2026, and 12,781,774 shares issued and outstanding as of December 31, 2025 | $1 | $1 |
| Additional paid-in capital | 31,020 | 30,386 |
| Retained earnings | 67,493 | 64,231 |
| Total stockholders' equity | 98,514 | 94,618 |
| Total liabilities and stockholders’ equity | $114,389 | $108,776 |
Item 1. Condensed Financial Statements
FAQ
- What is iRadimed's total equity?
- iRadimed (IRMD) reported total equity of $98.51M in Q1 2026.
- How has iRadimed's total equity changed year-over-year?
- iRadimed's total equity increased by 9.4% year-over-year, from $90.05M to $98.51M.
- What is the long-term trend for iRadimed's total equity?
- Over 5 years (2020 to 2025), iRadimed's total equity has grown at a 9.0% compound annual growth rate (CAGR), from $61.38M to $94.62M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about iRadimed's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude